The legal action, spearheaded by Hagens Berman, covers the period between July 30, 2025, and February 24, 2026. Plaintiffs allege that the company misled the market by downplaying FDA scrutiny, specifically framing a October 2025 Form 483 inspection as a minor administrative issue. During that time, CEO Sean Saint characterized the agency's concerns as limited to reporting definitions rather than actual device performance.
Beta Bionics Faces Securities Lawsuit Over iLet Safety Disclosures
Investors are targeting Beta Bionics in a federal class action lawsuit, alleging that management concealed thousands of safety complaints and life-threatening device malfunctions while aggressively marketing the iLet insulin delivery system as a user-friendly, highly automated solution to the public and potential shareholders.
This narrative collapsed on February 24, 2026, when the FDA released a formal warning letter detailing systemic failures at the company. The regulator found that Beta Bionics failed to analyze quality data regarding device malfunctions and neglected its legal obligation to report incidents involving serious injury or death within the mandatory 30-day window. Hagens Berman partner Reed Kathrein stated the investigation is scrutinizing whether the company prioritized revenue growth over patient safety. Investors who suffered losses during the class period have until November 3, 2026, to serve as lead plaintiffs.
Comments (0)
No comments yet. Be the first!